Tower Research Capital (TRC)’s Kazia Therapeutics KZIA Stock Holding History

Tower Research Capital (TRC)’s Portfolio KZIA Stock Details KZIA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-1	Closed	–	–	3518
2016 Q4	$0	Buy	+1	New	+$335	﹤0.01%	4146
2015 Q3	–	Sell	-52	Closed	-$42K	–	4417
2015 Q2	$42K	Buy	+52	New	+$59K	﹤0.01%	1505
2015 Q1	–	Sell	-2	Closed	-$1K	–	4682
2014 Q4	$1K	Sell	2 -9	-82%	-$4.46K	﹤0.01%	3666
2014 Q3	$6K	Hold	11	–	–	﹤0.01%	3168
2014 Q2	$8K	Buy	+11	New	+$8.45K	﹤0.01%	2522
2013 Q4	–	Hold	0	–	–	–	4714
2013 Q3	–	Sell	-9	Closed	-$7.03K	–	4701
2013 Q2	$8K	Buy	+9	New	+$8.1K	﹤0.01%	2566

Other funds holding KZIA

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Tower Research Capital (TRC)'s KZIA Position: Q1 2017 in Review

Tower Research Capital (TRC) sold out of Kazia Therapeutics (KZIA) in Q1 2017, closing a stake of 1 share.

Tower Research Capital (TRC) first reported a position in KZIA in Q2 2013 and held it in 6 quarters. The position peaked at $42K in Q2 2015. 7 funds tracked by Wall St. Rank hold KZIA as of Q1 2017.

Tower Research Capital (TRC) reported no remaining Kazia Therapeutics position as of Q1 2017 after selling out during the quarter.
Tower Research Capital (TRC) sold 1 Kazia Therapeutics share in Q1 2017.
Tower Research Capital (TRC) first reported a position in Kazia Therapeutics in Q2 2013 and held it in 6 quarters.
Tower Research Capital (TRC)'s Kazia Therapeutics position peaked at $42K in Q2 2015.
7 funds tracked by Wall St. Rank held Kazia Therapeutics as of Q1 2017.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2017, filed 19 May 2017.